Published in the Journal of Nanobiotechnology, the iPSC-derived therapy delivers BDNF mRNA to injured spinal tissue, improving motor recovery in preclinical studies.
Building on work at the University of Wisconsin-Madison, the Australian biotech company expects to release data from its Phase 3 iPSC-derived MSC KOA & Phase 2 Graft-vs-Host-Disease trials in the coming months.
Made Scientific will use RoosterBio's off-the-shelf MSCs, MSC expansion media, EV collection media, and related bioprocess expertise into its GMP operations.
The 38 projects include work in diabetes, cancer, Parkinson's disease, stroke, sickle cell disease, chronic pain, and cardiovascular, bone, blood, digestive, and neurological disorders
The company is working on iPSC-derived, AAV, and small molecule therapies for neurodegenerative, orthopedic, and blood-based disorders, with the help of OpenAI's models which seem to be accelerating life science research.
The site will also serve as the company's new headquarters, expanding its services in iPSC-based drug discovery, regenerative medicine, and cell therapy work.
The company is expanding its preclinical work on acute respiratory syndrome to investigate whether its fibroblasts may help with deadly lung inflammation, vascular leakage, and tissue damage.
The partnership hopes to speed up the scalable development of SC451 for type 1 diabetes by standardizing treatment protocols, improving clinical delivery and post-care, and preparing the therapy for broader use across...
The 4 US and 1 European patents cover the design and manufacturing of the company's placental therapies. The company is targeting various applications across orthopedics, urology, and wound care.
The therapy has been approved in the USA since 2024, and it'll soon be available down under as well, potentially reimbursed by Australia's pharma subsidy program.
